众生药业：目前昂拉地韦颗粒III期临床试验正在积极推进中

Core Viewpoint - The company is actively addressing the clinical needs for pediatric patients suffering from influenza, particularly in light of the rising cases of influenza A among children and associated health concerns [2]. Company Response - The company has acknowledged the significant clinical demand for pediatric medication and is currently advancing the Phase III clinical trial of its drug, Olanidavir granules [2]. - The company aims to complete the relevant research promptly and intends to apply for drug registration in compliance with applicable laws and regulations, thereby providing more treatment options for affected children [2].